FDA accepts Cogent's drug application with priority review for GIST treatment
Tweet Send to a Friend
Cogent Biosciences Inc. (NASDAQ: COGT) announced the U.S. Food and Drug Administration has accepted its New Drug Application for bezuclastinib ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


